Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
TARS Stock Chart & Stats
$68.16
$0.07(0.13%)
At close: 4:00 PM EST
$68.16
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $76.81
Previous CloseN/A
Volume127.14K
Average Volume (3M)654.27K
Market Cap
$2.79B
Enterprise Value$1.41B
Total Cash (Recent Filing)$381.14M
Total Debt (Recent Filing)$72.45M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Nov 05, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding42,214,108
10 Day Avg. Volume563,587
30 Day Avg. Volume654,271
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)9.27
Price to Sales (P/S)11.38
P/FCF Ratio-24.61
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit5.10
Enterprise Value/Ebitda-16.56
Forecast
1Y Price Target
$83.40Price Target Upside22.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Commercial GrowthNear-term commercial growth is expected based on ongoing direct-to-consumer advertising campaigns, which are targeting new prescriptions and directing efforts towards approximately 9 million Demodex blepharitis and overlapping ophthalmic disease patients.
Market PenetrationAnalyst's positive sentiment towards the ongoing XDEMVY launch has led to increased market penetration and revenue estimates due to the expansion of the prescriber base with over 20,000 eye care providers prescribing XDEMVY.
Sales PerformanceXDEMVY has achieved quarterly net product sales surpassing $100 million per quarter, reflecting its status as the first and only FDA-approved therapy to treat Demodex blepharitis.
Bears Say
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $38.51 and its highest was $76.81 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $2.79B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Nov 05, 2025 which is in 6 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Aug 06, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.379 by -$0.101.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 42,214,108 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.379. Following the earnings report the stock price went up 15.154%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.40 (22.36% Upside)
$83.40 (22.36% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 162.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 5.4%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
72.96%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
31.35%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of eye diseases. The company primarily operates within the ophthalmology sector, with a focus on addressing unmet medical needs through its proprietary product candidates. Tarsus is advancing its lead product, TP-03, aimed at treating Demodex blepharitis, a condition affecting the eyelids and eyelashes, and is exploring additional indications in the ophthalmic space.
TARS Company Deck
TARS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong sales performance and successful marketing efforts, indicating significant growth and expansion potential for XDEMVY. While there are challenges in managing expenses and gross-to-net improvements, the positive aspects, including financial stability and strategic pipeline development, outweigh the negatives.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$83.40
▲(22.36% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.23% Insiders
20.10% Mutual Funds
3.69% Other Institutional Investors
60.69% Public Companies and
Individual Investors